Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

QSI vs ACMR vs ICHR vs PACB vs ILMN

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
QSI
Quantum-Si incorporated

Biotechnology

HealthcareNASDAQ • US
Market Cap$193M
5Y Perf.-90.1%
ACMR
ACM Research, Inc.

Semiconductors

TechnologyNASDAQ • US
Market Cap$3.92B
5Y Perf.+115.0%
ICHR
Ichor Holdings, Ltd.

Semiconductors

TechnologyNASDAQ • US
Market Cap$2.47B
5Y Perf.+123.3%
PACB
Pacific Biosciences of California, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$498M
5Y Perf.-89.6%
ILMN
Illumina, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$21.07B
5Y Perf.-55.7%

QSI vs ACMR vs ICHR vs PACB vs ILMN — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
QSI logoQSI
ACMR logoACMR
ICHR logoICHR
PACB logoPACB
ILMN logoILMN
IndustryBiotechnologySemiconductorsSemiconductorsMedical - DevicesMedical - Diagnostics & Research
Market Cap$193M$3.92B$2.47B$498M$21.07B
Revenue (TTM)$2M$901M$959M$160M$4.39B
Net Income (TTM)$-104M$94M$-51M$-546M$853M
Gross Margin-200.5%44.4%11.3%28.2%67.1%
Operating Margin-62.1%12.1%-3.8%-346.1%20.9%
Forward P/E29.7x62.2x26.8x
Total Debt$4M$303M$186M$759M$2.55B
Cash & Equiv.$22M$766M$98M$64M$1.42B

QSI vs ACMR vs ICHR vs PACB vs ILMNLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

QSI
ACMR
ICHR
PACB
ILMN
StockNov 20May 26Return
Quantum-Si incorpor… (QSI)1009.9-90.1%
ACM Research, Inc. (ACMR)100215.0+115.0%
Ichor Holdings, Ltd. (ICHR)100223.3+123.3%
Pacific Biosciences… (PACB)10010.4-89.6%
Illumina, Inc. (ILMN)10044.3-55.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: QSI vs ACMR vs ICHR vs PACB vs ILMN

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ACMR and ILMN are tied at the top with 3 categories each (5-stock set) — the right choice depends on your priorities. Illumina, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. ICHR also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
QSI
Quantum-Si incorporated
The Defensive Pick

QSI is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 3.79, Low D/E 1.9%, current ratio 7.64x
Best for: sleep-well-at-night
ACMR
ACM Research, Inc.
The Income Pick

ACMR carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 3 yrs, beta 3.24, yield 0.2%
  • Rev growth 15.2%, EPS growth -10.5%, 3Y rev CAGR 32.3%
  • 30.7% 10Y total return vs ICHR's 6.3%
  • PEG 0.84 vs ILMN's 6.33
Best for: income & stability and growth exposure
ICHR
Ichor Holdings, Ltd.
The Momentum Pick

ICHR ranks third and is worth considering specifically for momentum.

  • +329.1% vs QSI's -18.3%
Best for: momentum
PACB
Pacific Biosciences of California, Inc.
The Defensive Pick

PACB is the clearest fit if your priority is defensive.

  • Beta 2.43, current ratio 6.89x
Best for: defensive
ILMN
Illumina, Inc.
The Quality Compounder

ILMN is the #2 pick in this set and the best alternative if quality and stability is your priority.

  • 19.4% margin vs QSI's -56.1%
  • Beta 1.23 vs ICHR's 3.93
  • 13.4% ROA vs PACB's -66.8%, ROIC 16.8% vs -45.8%
Best for: quality and stability
See the full category breakdown
CategoryWinnerWhy
GrowthACMR logoACMR15.2% revenue growth vs QSI's -20.3%
ValueACMR logoACMRBetter valuation composite
Quality / MarginsILMN logoILMN19.4% margin vs QSI's -56.1%
Stability / SafetyILMN logoILMNBeta 1.23 vs ICHR's 3.93
DividendsACMR logoACMR0.2% yield; 3-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)ICHR logoICHR+329.1% vs QSI's -18.3%
Efficiency (ROA)ILMN logoILMN13.4% ROA vs PACB's -66.8%, ROIC 16.8% vs -45.8%

QSI vs ACMR vs ICHR vs PACB vs ILMN — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

QSIQuantum-Si incorporated
FY 2025
Product
93.8%$2M
Service
6.2%$150,000
ACMRACM Research, Inc.
FY 2025
Total Single Wafer and Semi-Critical Cleaning Equipment
69.5%$626M
ECP Front End And Packaging Furnace And Other Technologies
22.1%$200M
Advanced Packaging (exclude ECP), Services & Spares
8.4%$76M
ICHRIchor Holdings, Ltd.

Segment breakdown not available.

PACBPacific Biosciences of California, Inc.
FY 2025
Product
45.9%$136M
Consumable
27.7%$82M
Instrument
18.2%$54M
Service And Other
8.2%$24M
ILMNIllumina, Inc.
FY 2025
Sequencing
91.8%$4.0B
Microarray
8.2%$358M

QSI vs ACMR vs ICHR vs PACB vs ILMN — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLACMRLAGGINGPACB

Income & Cash Flow (Last 12 Months)

ILMN leads this category, winning 4 of 6 comparable metrics.

ILMN is the larger business by revenue, generating $4.4B annually — 2371.0x QSI's $2M. ILMN is the more profitable business, keeping 19.4% of every revenue dollar as net income compared to QSI's -56.1%. On growth, PACB holds the edge at +13.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…ILMN logoILMNIllumina, Inc.
RevenueTrailing 12 months$2M$901M$959M$160M$4.4B
EBITDAEarnings before interest/tax-$112M$126M-$11M-$169M$1.1B
Net IncomeAfter-tax profit-$104M$94M-$51M-$546M$853M
Free Cash FlowCash after capex-$96M-$69M-$17M-$124M$989M
Gross MarginGross profit ÷ Revenue-2.0%+44.4%+11.3%+28.2%+67.1%
Operating MarginEBIT ÷ Revenue-62.1%+12.1%-3.8%-3.5%+20.9%
Net MarginNet income ÷ Revenue-56.1%+10.4%-5.3%-3.4%+19.4%
FCF MarginFCF ÷ Revenue-51.7%-7.6%-1.7%-77.4%+22.5%
Rev. Growth (YoY)Latest quarter vs prior year-69.4%+9.4%+4.7%+13.8%+4.8%
EPS Growth (YoY)Latest quarter vs prior year+9.1%-76.1%+46.2%+6.1%
ILMN leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — ICHR and ILMN each lead in 2 of 6 comparable metrics.

At 25.5x trailing earnings, ILMN trades at a 41% valuation discount to ACMR's 43.2x P/E. Adjusting for growth (PEG ratio), ACMR offers better value at 1.22x vs ILMN's 6.01x — a lower PEG means you pay less per unit of expected earnings growth.

MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…ILMN logoILMNIllumina, Inc.
Market CapShares × price$193M$3.9B$2.5B$498M$21.1B
Enterprise ValueMkt cap + debt − cash$175M$3.5B$2.6B$1.2B$22.2B
Trailing P/EPrice ÷ TTM EPS-1.92x43.21x-46.25x-0.91x25.45x
Forward P/EPrice ÷ next-FY EPS est.29.68x62.25x26.77x
PEG RatioP/E ÷ EPS growth rate1.22x6.01x
EV / EBITDAEnterprise value multiple27.49x19.58x
Price / SalesMarket cap ÷ Revenue79.07x4.35x2.61x3.11x4.86x
Price / BookPrice ÷ Book value/share0.88x2.06x3.67x92.53x7.95x
Price / FCFMarket cap ÷ FCF22.63x
Evenly matched — ICHR and ILMN each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

ILMN leads this category, winning 5 of 9 comparable metrics.

ILMN delivers a 32.8% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $-11 for PACB. QSI carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to PACB's 141.98x. On the Piotroski fundamental quality scale (0–9), ILMN scores 8/9 vs ACMR's 2/9, reflecting strong financial health.

MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…ILMN logoILMNIllumina, Inc.
ROE (TTM)Return on equity-47.3%+6.1%-7.5%-11.2%+32.8%
ROA (TTM)Return on assets-42.7%+3.9%-5.2%-66.8%+13.4%
ROICReturn on invested capital-38.1%+7.0%-3.9%-45.8%+16.8%
ROCEReturn on capital employed-42.9%+6.6%-4.7%-58.0%+17.6%
Piotroski ScoreFundamental quality 0–922338
Debt / EquityFinancial leverage0.02x0.16x0.28x141.98x0.94x
Net DebtTotal debt minus cash-$17M-$463M$87M$696M$1.1B
Cash & Equiv.Liquid assets$22M$766M$98M$64M$1.4B
Total DebtShort + long-term debt$4M$303M$186M$759M$2.6B
Interest CoverageEBIT ÷ Interest expense20.44x-5.97x-77.95x12.09x
ILMN leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ACMR leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ACMR five years ago would be worth $23,344 today (with dividends reinvested), compared to $663 for PACB. Over the past 12 months, ICHR leads with a +329.1% total return vs QSI's -18.3%. The 3-year compound annual growth rate (CAGR) favors ACMR at 80.5% vs PACB's -48.7% — a key indicator of consistent wealth creation.

MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…ILMN logoILMNIllumina, Inc.
YTD ReturnYear-to-date-15.5%+31.9%+249.0%-10.3%+3.2%
1-Year ReturnPast 12 months-18.3%+195.6%+329.1%+46.0%+81.7%
3-Year ReturnCumulative with dividends-31.9%+487.9%+151.1%-86.5%-27.1%
5-Year ReturnCumulative with dividends-90.6%+133.4%+28.9%-93.4%-62.8%
10-Year ReturnCumulative with dividends-90.1%+3065.8%+629.1%-81.3%+0.7%
CAGR (3Y)Annualised 3-year return-12.0%+80.5%+35.9%-48.7%-10.0%
ACMR leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ICHR and ILMN each lead in 1 of 2 comparable metrics.

ILMN is the less volatile stock with a 1.23 beta — it tends to amplify market swings less than ICHR's 3.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICHR currently trades 97.7% from its 52-week high vs QSI's 31.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…ILMN logoILMNIllumina, Inc.
Beta (5Y)Sensitivity to S&P 5003.79x3.24x3.93x2.43x1.23x
52-Week HighHighest price in past year$3.10$71.65$72.87$2.73$155.53
52-Week LowLowest price in past year$0.69$19.26$13.12$0.85$73.86
% of 52W HighCurrent price vs 52-week peak+31.6%+82.6%+97.7%+60.4%+89.2%
RSI (14)Momentum oscillator 0–10058.960.766.960.265.2
Avg Volume (50D)Average daily shares traded4.4M1.2M795K5.9M1.5M
Evenly matched — ICHR and ILMN each lead in 1 of 2 comparable metrics.

Analyst Outlook

ACMR leads this category, winning 1 of 1 comparable metric.

Analyst consensus: QSI as "Buy", ACMR as "Buy", ICHR as "Buy", PACB as "Buy", ILMN as "Buy". Consensus price targets imply 6.3% upside for ILMN (target: $147) vs -39.4% for PACB (target: $1). ACMR is the only dividend payer here at 0.19% yield — a key consideration for income-focused portfolios.

MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…ILMN logoILMNIllumina, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$1.00$40.00$49.80$1.00$147.38
# AnalystsCovering analysts210141850
Dividend YieldAnnual dividend ÷ price+0.2%
Dividend StreakConsecutive years of raises31
Dividend / ShareAnnual DPS$0.11
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.2%0.0%0.0%+3.5%
ACMR leads this category, winning 1 of 1 comparable metric.
Key Takeaway

ILMN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ACMR leads in 2 (Total Returns, Analyst Outlook). 2 tied.

Best OverallACM Research, Inc. (ACMR)Leads 2 of 6 categories
Loading custom metrics...

QSI vs ACMR vs ICHR vs PACB vs ILMN: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is QSI or ACMR or ICHR or PACB or ILMN a better buy right now?

For growth investors, ACM Research, Inc.

(ACMR) is the stronger pick with 15. 2% revenue growth year-over-year, versus -20. 3% for Quantum-Si incorporated (QSI). Illumina, Inc. (ILMN) offers the better valuation at 25. 5x trailing P/E (26. 8x forward), making it the more compelling value choice. Analysts rate Quantum-Si incorporated (QSI) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — QSI or ACMR or ICHR or PACB or ILMN?

On trailing P/E, Illumina, Inc.

(ILMN) is the cheapest at 25. 5x versus ACM Research, Inc. at 43. 2x. On forward P/E, Illumina, Inc. is actually cheaper at 26. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ACM Research, Inc. wins at 0. 84x versus Illumina, Inc. 's 6. 33x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — QSI or ACMR or ICHR or PACB or ILMN?

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +133. 4%, compared to -93. 4% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus QSI's -90. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — QSI or ACMR or ICHR or PACB or ILMN?

By beta (market sensitivity over 5 years), Illumina, Inc.

(ILMN) is the lower-risk stock at 1. 23β versus Ichor Holdings, Ltd. 's 3. 93β — meaning ICHR is approximately 218% more volatile than ILMN relative to the S&P 500. On balance sheet safety, Quantum-Si incorporated (QSI) carries a lower debt/equity ratio of 2% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — QSI or ACMR or ICHR or PACB or ILMN?

By revenue growth (latest reported year), ACM Research, Inc.

(ACMR) is pulling ahead at 15. 2% versus -20. 3% for Quantum-Si incorporated (QSI). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -140. 6% for Ichor Holdings, Ltd.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — QSI or ACMR or ICHR or PACB or ILMN?

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -41. 6% for Quantum-Si incorporated — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -39. 8% for QSI. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is QSI or ACMR or ICHR or PACB or ILMN more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ACM Research, Inc. (ACMR) is the more undervalued stock at a PEG of 0. 84x versus Illumina, Inc. 's 6. 33x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Illumina, Inc. (ILMN) trades at 26. 8x forward P/E versus 62. 2x for Ichor Holdings, Ltd. — 35. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ILMN: 6. 3% to $147. 38.

08

Which pays a better dividend — QSI or ACMR or ICHR or PACB or ILMN?

In this comparison, ACMR (0.

2% yield) pays a dividend. QSI, ICHR, PACB, ILMN do not pay a meaningful dividend and should not be held primarily for income.

09

Is QSI or ACMR or ICHR or PACB or ILMN better for a retirement portfolio?

For long-horizon retirement investors, Illumina, Inc.

(ILMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 23)). Quantum-Si incorporated (QSI) carries a higher beta of 3. 79 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ILMN: +0. 7%, QSI: -90. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between QSI and ACMR and ICHR and PACB and ILMN?

These companies operate in different sectors (QSI (Healthcare) and ACMR (Technology) and ICHR (Technology) and PACB (Healthcare) and ILMN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: QSI is a small-cap quality compounder stock; ACMR is a small-cap high-growth stock; ICHR is a small-cap quality compounder stock; PACB is a small-cap quality compounder stock; ILMN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

QSI

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ACMR

Steady Growth Compounder

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Stocks Like

ICHR

Quality Business

  • Sector: Technology
  • Market Cap > $100B
Run This Screen
Stocks Like

PACB

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 16%
Run This Screen
Stocks Like

ILMN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 11%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform QSI and ACMR and ICHR and PACB and ILMN on the metrics below

Revenue Growth>
%
(QSI: -69.4% · ACMR: 9.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.